May 8th 2024
Phase 2 data also highlight an improvement in disease control rate with setanaxib/pembrolizumab in squamous cell carcinoma of the head and neck.
DART Meets Noninferiority PFS Benchmark in HPV-Related OPSCC
February 25th 2022In a pre-planned pooled analysis of data from the MC1273 and MC1675 trials presented at the 2022 ASTRO Multidisciplinary Head and Neck Cancers Symposium, de-escalated adjuvant radiation therapy met criteria for efficacy in human papillomavirus–related oropharyngeal squamous cell carcinoma.
Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16th 2021Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21st 2021A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.